

## Patent Case No. IN0964Q

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Carlos O. Stalgis et al.

Examiner: Shanon A. Foley

For: RIBAVIRIN-PEGYLATED INTERFERON ALFA INDUCTION HCV COMBINATION THERAPY

Group Art Unit:

1648

Serial No.: 09/464,426

Filed: 12/16/99

COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria VA 22313-1450

Sir:

## <u>AMENDMENT</u>

This is in response to the Official Action, dated 02/10/2004, stating that the application fails to comply with the requirements of 37 C.F.R.§§1.821-1.825.

Applicants are amending this application to add the sequence listing and are enclosing herewith the following:

- (1) A computer readable form ("CRF") of the sequence listing;
- (2) A paper copy of the sequence listing;
- (3) A SEQUENCE LISTING STATEMENT;
- (4) A Petition and Fee for a One Month Extension of Time to Respond,
- (5) A copy of the Notice to comply with Requirements for patent applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures,
- (6) A Transmittal Letter; and
- (7) A return postcard.